Ending of US weight-loss drug shortages prompts compounder complaints

Novo Nordisk’s semaglutide diabetes and weight loss drugs, Ozempic and Wegovy, are no longer officially in shortage in the US, according to the US Food and Drug Administration (FDA). That means that compounding pharmacies and outsourcing facilities that had been legitimately preparing their own versions of the drugs will no longer be permitted to do so. Groups representing those suppliers have protested the decision, saying supplies are still tight.